Dr. Gary Gustafson spent 25 years as a Medicinal Chemist in the industry and was part of a team that produced the recently FDA-approved drug, Olutasidenib. Since joining CAS in 2019, Gary has helped scientists derive maximum benefit from CAS solutions. Also contributes to the CAS product teams, helping to design new capabilities and enhance existing ones.
He obtained his PhD in Chemistry at Brown University and completed a Postdoctoral Position in Organic Chemistry and Biochemistry at the University of Virginia.
